Perioperative intravitreal triamcinolone in phacoemulsification for concurrent clinically significant diabetic macular oedema

Record Provided by the NHSTCT Register - 2007 Update - Department of Health0 sites56 target enrollmentSeptember 28, 2007

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Record Provided by the NHSTCT Register - 2007 Update - Department of Health
Enrollment: 56
Status: Completed
Last Updated: 8 years ago

No summary available.

Registry

who.int

Start Date

September 28, 2007

End Date

August 31, 2008

Last Updated

8 years ago

Study Type

Interventional

Sponsor

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

•1\. Patients with Diabetic Mellitus, Type 1 or 2 Eligible
•2\. Patients with cataract sufficient in an eye to cause visual symptoms
•3\. Patients who have persistent CSME despite previous later treatment
•4\. Patients who have moderate or severs NPDR and treated PDR as defined by a clinical modification of the Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy scale
•5\. OCT measurements of \<300 micron at central subfold of fats macula map

•1\. Patients with no CSME
•2\. High risk proliferative retinopathy as defined by the DRS 17
•3\. Diabetes associated with specific genetic conditions, induced by drugs, chemicals or endocrinopathies
•4\. Coexistent ocular disease
•5\. Coexistent disease likely to affect retinopathy progression, for example severe carotid occlusive disease
•6\. Patients with coexistent disease likely to respond poorly to side effects of intravitreal triamcinalone, including glaucoma, OHT, steroid responders
•7\. Prior intraocular surgery to either eye
•8\. Complicated cataract surgery